LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity-Reference-Cited by-同舟云学术

LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity

Published:2024-08 Issue:16 Volume:187 Page:4355-4372.e22
ISSN:0092-8674
Container-title:Cell
language:en
Short-container-title:Cell

Author:

Andrews Lawrence P.,Butler Samuel C.,Cui Jian,Cillo Anthony R.,Cardello Carly,Liu Chang,Brunazzi Erin A.,Baessler Andrew,Xie Bingxian,Kunning Sheryl R.,Ngiow Shin Foong,Huang Yinghui Jane,Manne Sasikanth,Sharpe Arlene H.,Delgoffe Greg M.,Wherry E. John,Kirkwood John M.,Bruno Tullia C.,Workman Creg J.,Vignali Dario A.A.

Publisher

Elsevier BV

Reference57 articles.

1. The PD-1 pathway in tolerance and autoimmunity;Francisco;Immunol. Rev.,2010

2. LAG3 (CD223) as a cancer immunotherapy target;Andrews;Immunol. Rev.,2017

3. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab;Topalian;J. Clin. Oncol.,2014

4. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma;Tawbi;N. Engl. J. Med.,2022

5. Neoadjuvant relatlimab and nivolumab in resectable melanoma;Amaria;Nature,2022

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer;Cancers;2024-09-04

2. LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity;Cell;2024-08

3. Anti-LAG-3 boosts CD8 T cell effector function;Cell;2024-08

4. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity;Cell;2024-08